Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Linifanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 0.94 |
| ▸ | FLT3 known ✓ | P36888 | 16/20 | 0.94 |
| ▸ | CSF1R known ✓ | P07333 | 10/20 | 0.94 |
| ▸ | FLT4 known ✓ | P35916 | 10/20 | 0.94 |
| ▸ | FLT1 known ✓ | P17948 | 9/20 | 0.94 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.94 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.94 |
| ▸ | KIT | P10721 | 14/20 | 0.94 |
| ▸ | LYN | P07948 | 7/20 | 0.94 |
| ▸ | SRC | P12931 | 6/20 | 0.94 |
| ▸ | BLK | P51451 | 6/20 | 0.94 |
| ▸ | AURKA | O14965 | 5/20 | 0.94 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.94 |
| ▸ | PLK4 | O00444 | 4/20 | 0.94 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.94 |
| ▸ | MET | P08581 | 4/20 | 0.94 |
| ▸ | PRKACA | P17612 | 4/20 | 0.94 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.94 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.94 |
| ▸ | STK3 | Q13188 | 4/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linifanib SCHEMBL93804 | 0.97 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL29375368 | 0.97 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL1880038 | 0.96 | KDR (0.98) | KDRFLT3KITCSF1RFLT4 | |
| Alcohol SCHEMBL16817140 | 0.89 | KDR (0.80) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL423390 | 0.88 | KDR (0.77) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL421934 | 0.88 | KDR (0.82) | KDRFLT3KITCSF1RFLT4 | |
| Alcohol SCHEMBL16817141 | 0.88 | KDR (0.81) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL422778 | 0.87 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL420765 | 0.87 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL16303695 | 0.87 | KDR (0.78) | KDRFLT3KITCSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994208-B2 | Crystalline chemotherapeutic | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | claimed |
| EP-2195300-A1 | CRYSTALLINE CHEMOTHERAPEUTIC | Abbott Laboratories (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090105326-A1 | Crystalline Chemotherapeutic | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | claimed |
| WO-2009052225-A1 | CRYSTALLINE CHEMOTHERAPEUTIC | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | WO | claimed |
| EP-2195300-B1 | CRYSTALLINE CHEMOTHERAPEUTIC | ABBVIE BAHAMAS LTD (BS) | 2015-06-24 | — | — | EP | disclosed |
| US-7994208-B2 | Crystalline chemotherapeutic | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994208-B2 | Crystalline chemotherapeutic | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2195300-A1 | CRYSTALLINE CHEMOTHERAPEUTIC | Abbott Laboratories (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-2195300-A1 | CRYSTALLINE CHEMOTHERAPEUTIC | Abbott Laboratories (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100143459-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-2089003-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | Abbott GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009100176-A2 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203709-A1 | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090105326-A1 | Crystalline Chemotherapeutic | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105326-A1 | Crystalline Chemotherapeutic | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009052225-A1 | CRYSTALLINE CHEMOTHERAPEUTIC | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052225-A1 | CRYSTALLINE CHEMOTHERAPEUTIC | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008055966-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | ABBOTT GMBH & CO. KG (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203709-A1 | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor | SRC, LYN, SYK | KDR 144/4885FLT3 9/4885CSF1R 537/4885 |
| US-20100143459-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | SRC, LYN, SYK | KDR 144/4885FLT3 9/4885CSF1R 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.